Progress in research on paclitaxel and tumor immunotherapy

[1]  L. Sheng,et al.  Efficacy and safety of liposome-paclitaxel and carboplatin based concurrent chemoradiotherapy for locally advanced lung squamous cell carcinoma , 2018, Cancer Chemotherapy and Pharmacology.

[2]  K. Lam,et al.  Nanoformulated paclitaxel and AZD9291 synergistically eradicate non-small-cell lung cancers in vivo. , 2018, Nanomedicine.

[3]  Tingting Liu,et al.  The efficacy and safety of paclitaxel and carboplatin with versus without bevacizumab in patients with non-small-cell lung cancer: a systematic review and meta-analysis , 2017, Oncotarget.

[4]  K. Bélanger,et al.  Peripheral and local predictive immune signatures identified in a phase II trial of ipilimumab with carboplatin/paclitaxel in unresectable stage III or stage IV melanoma , 2017, Journal of Immunotherapy for Cancer.

[5]  T. Sakurai,et al.  Peptide-pulsed dendritic cell vaccine in combination with carboplatin and paclitaxel chemotherapy for stage IV melanoma , 2017, Melanoma research.

[6]  Ting Gong,et al.  Advances in exploring alternative Taxol sources , 2016 .

[7]  Gregory Stephanopoulos,et al.  Overcoming heterologous protein interdependency to optimize P450-mediated Taxol precursor synthesis in Escherichia coli , 2016, Proceedings of the National Academy of Sciences.

[8]  Kan Chen,et al.  Autophagy regulates resistance of non-small cell lung cancer cells to paclitaxel , 2016, Tumor Biology.

[9]  C. Fu,et al.  A systematic approach to expound the variations in taxane production under different dissolved oxygen conditions in Taxus chinensis cells , 2016, Plant Cell Reports.

[10]  G. Loake,et al.  Cambial meristematic cells: a platform for the production of plant natural products. , 2015, New biotechnology.

[11]  Haijun Zhang.  Apatinib for molecular targeted therapy in tumor , 2015, Drug design, development and therapy.

[12]  Qi Zhou,et al.  MiR-197 induces Taxol resistance in human ovarian cancer cells by regulating NLK , 2015, Tumor Biology.

[13]  G. Getz,et al.  RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer , 2015, Nature Communications.

[14]  M. Socinski,et al.  Quality of Life Analyses from the Randomized, Open-Label, Phase III PointBreak Study of Pemetrexed-Carboplatin-Bevacizumab followed by Maintenance Pemetrexed-Bevacizumab Versus Paclitaxel-Carboplatin-Bevacizumab followed by Maintenance Bevacizumab in Patients with Stage IIIB or IV Nonsquamous Non–Sm , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[15]  C. Lo,et al.  Amnion cell-mediated immune modulation following bleomycin challenge: controlling the regulatory T cell response , 2015, Stem Cell Research & Therapy.

[16]  G. Çok,et al.  A retrospective comparison of docetaxel and paclitaxel as single-agent second-line chemotherapy for advanced stage non-small cell lung cancer , 2014 .

[17]  T. Takeshita,et al.  A low, non-toxic dose of paclitaxel can prevent dendritic cell-precursors from becoming tolerogenic dendritic cells with impaired functions. , 2014, Biomedical research.

[18]  K. Herrmann,et al.  Intensified Neoadjuvant Chemotherapy with Nab-Paclitaxel plus Gemcitabine Followed by FOLFIRINOX in a Patient with Locally Advanced Unresectable Pancreatic Cancer , 2014, Case Reports in Oncology.

[19]  B. Weaver,et al.  How Taxol/paclitaxel kills cancer cells , 2014, Molecular biology of the cell.

[20]  Satpal Singh,et al.  Rethinking production of Taxol® (paclitaxel) using endophyte biotechnology. , 2014, Trends in biotechnology.

[21]  J. Mackey,et al.  Presentation and management of docetaxel-related adverse effects in patients with breast cancer , 2014, Cancer management and research.

[22]  G. Loake,et al.  Paclitaxel: biosynthesis, production and future prospects. , 2014, New biotechnology.

[23]  M. Piccart,et al.  A randomized controlled phase II trial of a novel composition of paclitaxel embedded into neutral and cationic lipids targeting tumor endothelial cells in advanced triple-negative breast cancer (TNBC). , 2014 .

[24]  Z. Dong,et al.  Paclitaxel: new uses for an old drug , 2014, Drug design, development and therapy.

[25]  G. Choi,et al.  Combined Treatment of Murine Fibrosarcoma with Chemotherapy (Paclitaxel), Radiotherapy, and Intratumoral Injection of Dendritic Cells , 2014, Annals of dermatology.

[26]  Myung Chul Choi,et al.  Transformation of taxol-stabilized microtubules into inverted tubulin tubules triggered by a tubulin conformation switch , 2014, Nature materials.

[27]  Ming Yao,et al.  Efficient synthesis of α-quaternary α-hydroxy-β-amino esters via silyl glyoxylate-mediated three-component reactions. , 2014, Organic letters.

[28]  R. Franco,et al.  Activity of gefitinib in a non-small-cell lung cancer patient with both activating and resistance EGFR mutations. , 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[29]  S. Jennewein,et al.  Getting to the bottom of Taxol biosynthesis by fungi , 2013, Fungal Diversity.

[30]  F. Koehn.  Natural Products and Cancer Drug Discovery , 2013 .

[31]  T. Kapoor,et al.  Microtubule attachment and spindle assembly checkpoint signalling at the kinetochore , 2012, Nature Reviews Molecular Cell Biology.

[32]  J. Ritz,et al.  Bortezomib-based graft-versus-host disease prophylaxis in HLA-mismatched unrelated donor transplantation. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  Kit S Lam,et al.  Well-defined, reversible disulfide cross-linked micelles for on-demand paclitaxel delivery. , 2011, Biomaterials.

[34]  I. Schmidt-Wolf,et al.  Combining cytokine-induced killer cells with vaccination in cancer immunotherapy: more than one plus one? , 2011, Leukemia research.

[35]  C. Figdor,et al.  Platinum-based drugs disrupt STAT6-mediated suppression of immune responses against cancer in humans and mice. , 2011, The Journal of clinical investigation.

[36]  G. Giaccone,et al.  Phase II study of belinostat in patients with recurrent or refractory advanced thymic epithelial tumors. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  G. Loake,et al.  Cultured cambial meristematic cells as a source of plant natural products , 2010, Nature Biotechnology.

[38]  M. Socinski,et al.  A Dose Finding Study of Weekly and Every-3-Week nab-Paclitaxel Followed by Carboplatin as First-Line Therapy in Patients with Advanced Non-small Cell Lung Cancer , 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[39]  L. Davidson,et al.  Regulation of mammary epithelial architecture by PTEN , 2010, Breast Cancer Research.

[40]  K. Tang,et al.  A review: recent advances and future prospects of taxol-producing endophytic fungi , 2010, Applied Microbiology and Biotechnology.

[41]  A. Aboussekhra,et al.  Doxorubicin downregulates cell surface B7-H1 expression and upregulates its nuclear expression in breast cancer cells: role of B7-H1 as an anti-apoptotic molecule , 2010, Breast Cancer Research.

[42]  Jun Shi,et al.  The immunologic aspects in advanced ovarian cancer patients treated with paclitaxel and carboplatin chemotherapy , 2010, Cancer Immunology, Immunotherapy.

[43]  Wenqiang Chen,et al.  Isolation and characterization of endophytic taxol-producing fungi from Taxus chinensis , 2009, Journal of Industrial Microbiology & Biotechnology.

[44]  N. Barua,et al.  Synthesis of the C‐13 Side‐Chain of Taxol , 2008 .

[45]  C. Allen,et al.  Effects of sustained and intermittent paclitaxel therapy on tumor repopulation in ovarian cancer , 2008, Molecular Cancer Therapeutics.

[46]  Susan C. Roberts,et al.  Production and engineering of terpenoids in plant cell culture. , 2007, Nature chemical biology.

[47]  N. Barua,et al.  Synthesis of the C-13 Side-Chain of Taxol , 2007 .

[48]  William C Hahn,et al.  Oncogenic Transformation by Inhibitor-Sensitive and -Resistant EGFR Mutants , 2005, PLoS medicine.

[49]  S. Swain,et al.  A phase II trial of paclitaxel (Taxol®) as first line treatment in advanced breast cancer , 2004, Investigational New Drugs.

[50]  Cheng Yi-jian.  Screening endophytic fungus to produce taxol from Taxus Yunnanensis , 2003 .

[51]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..

[52]  J Verweij,et al.  Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. , 2001, European journal of cancer.

[53]  R. Croteau,et al.  Engineering Escherichia coli for the synthesis of taxadiene, a key intermediate in the biosynthesis of taxol. , 2001, Bioorganic & medicinal chemistry.

[54]  S. R. Datta,et al.  Cellular survival: a play in three Akts. , 1999, Genes & development.

[55]  W. Denny,et al.  A 2-nitroimidazole carbamate prodrug of 5-amimo-1-(chloromethyl)-3-[(5,6,7-trimethoxyindol-2-yl)carbony l]-1,2-dihydro-3H--benz[E]indole (amino-seco-CBI-TMI) for use with ADEPT and GDEPT. , 1999, Bioorganic & medicinal chemistry letters.

[56]  Ronald J. Biediger,et al.  First total synthesis of taxol. 1. Functionalization of the B ring , 1994 .

[57]  A. Stierle,et al.  Taxol and taxane production by Taxomyces andreanae, an endophytic fungus of Pacific yew. , 1993, Science.

[58]  A. Greene,et al.  Highly efficient, practical approach to natural taxol , 1988 .

[59]  A. McPhail,et al.  Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. , 1971, Journal of the American Chemical Society.

[60]  A. Bose,et al.  Nuclear Magnetic Resonance Spectroscopy. III. Structure of Phenyldiazonium Ion from 15N-H Coupling Study1 , 1966 .